Loading...
OTCM
RGMP
Market cap0kUSD
Jul 12, Last price  
0.00USD
Name

Regnum Corp

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
18,10021,4006,3009,00000
Net income
-781k
L+189.40%
1,3871,998-36,380-117,673-269,830-780,887
CFO
-706k
L+5,992.28%
3,0504,045-38,851-3,672-11,581-705,547

Profile

Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
IPO date
Mar 15, 2019
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT